The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
A new quantitative systems pharmacology model spanning all three classes of BRAF-mutant lung cancer predicts that MEK-ERK ...
Braftovi plus Erbitux and FOLFIRI showed significant ORR benefits in BRAF V600E–mutant mCRC compared to the control regimen. The combination therapy achieved a confirmed ORR of 64.4% versus 39.2% with ...
DURHAM, N.C. and ALISO VIEJO, Calif., Jan. 28, 2014 /PRNewswire/ -- bioMerieux, Inc. and Clarient, a GE Healthcare Company today announced that bioMerieux's molecular diagnostic test THxID®-BRAF has ...
The combination is the first and only therapy to be approved with a tumor-agnostic indication in both children and adults with solid tumors that have a BRAF V600E mutation, Novartis said late ...
"As a leader in cancer diagnostics, Ventana is committed to providing unique immunohistochemistry assays for aiding in the diagnosis and management of a variety of cancers," says Ventana President ...
The BREAKWATER trial showed significant improvement in progression-free survival with Braftovi, Erbitux, and mFOLFOX6 in mCRC patients with BRAF V600E mutations. Median overall survival was 30.3 ...
EAST HANOVER, N.J., June 22, 2017 /PRNewswire/ -- Novartis today announced the US Food and Drug Administration (FDA) approval of Tafinlar ® (dabrafenib) in combination with Mekinist ® (trametinib) to ...
First-line treatment with the triplet combination of encorafenib, cetuximab and mFOLFOX6 significantly improved survival compared to the standard of care in patients with BRAF V600E-mutated metastatic ...
Results from a phase 1/2a trial and the ongoing FORTE basket study support the FDA’s regulatory decision for these patients with recurrent or progressive glioma. “High-grade gliomas are aggressive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results